OGS Alters Plans to Enter Protein Microarray Market, Shifts Focus to Making Drugs | GenomeWeb

NEW YORK, March 15 – Oxford Glycosciences of Oxford, UK, has apparently changed its plans for entering the protein microarray market, saying Thursday that their collaboration with Packard Biosciences and Cambridge Antibody Technologies is “just a research project” and that the company has no immediate plans to commercialize the technology. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.